# OnCo record paper-garnet-dostarlimab-oaknin-jama-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-garnet-dostarlimab-oaknin-jama-oncol-2020" ;
  schema:name "GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer"@en ;
  schema:description "The PD-1 antibody dostarlimab shrank tumours in about four in ten women with mismatch repair-deficient endometrial cancer that had progressed after platinum chemotherapy, with most responses still ongoing after a year."@en ;
  schema:url <https://onco.cc/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2020.4515>, <https://pubmed.ncbi.nlm.nih.gov/33001143/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2020.4515> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Oaknin A, Tinker AV, Gilbert L, et al." ;
  onco:cancers <https://onco.cc/cancers/endometrial-mmr-deficient/> ;
  onco:drugs <https://onco.cc/drugs/dostarlimab/> ;
  onco:trials <https://onco.cc/trials/garnet/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .